MedTrace Logo

Vinorelbine, Cisplatin, Disulfiram and Copper in CTC_EMT Positive Refractory Metastatic Breast Cancer.

NCT04265274 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2023-10-06

No results posted yet for this study

Summary

This is a proof-of-concept study to define efficacy of vinorelbine, cisplatin, disulfiram and copper in CTC\_EMT positive refractory metastatic hormone receptor positive, HER2 negative breast cancer.

Conditions

Interventions

DRUG

Disulfiram

dosing 400mg daily

DRUG

Vinorelbin

25mg/m2 day 1 and 8,

DRUG

Cisplatin

75mg/m2 day 1

DRUG

Copper

2 mg of elementary Copper daily

Sponsors & Collaborators

  • National Cancer Institute, Slovakia

    lead OTHER_GOV

Principal Investigators

  • Michal Mego, Prof · National Cancer Institute, Slovakia

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-01
Primary Completion
2022-01-01
Completion
2023-01-01

Countries

  • Slovakia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04265274 on ClinicalTrials.gov